Subscribe to Newsletter

Discovery & Development

Discovery & Development Drug Discovery

Cell Therapy Team Up

| Jamie Irvine | 2 min read

Thermo Fisher Scientific and UCSF launch new cell therapy manufacturing site to accelerate advanced cell therapies development

Discovery & Development Drug Delivery

Clever Chemistry and Cages

| Jamie Irvine | 3 min read

Self-assembling “super-sized” nanocages could encapsulate and deliver drugs to specific targets in the body.

Discovery & Development Drug Discovery

Lung Cancer Collaboration

| Jamie Irvine | 2 min read

The Lung Cancer Research Foundation has partnered with Daiichi Sankyo and AstraZeneca to offer grants for research exploring ADCs against lung cancer

Discovery & Development Formulation

Superbugs Versus Supercomputers

| Jamie Irvine | 2 min read

Developments in antivirulence drug treatments could solve the threat of antimicrobial resistance

Discovery & Development Drug Discovery

How Custom Antibody Libraries Empower Therapeutic Antibody Bioassays

| Sponsored by Bio-Rad Laboratories | 6 min read

There are many ways to generate antibodies, but sometimes traditional methods don’t deliver what you need.

Discovery & Development Formulation

The Fountain of Youth

| Jamie Irvine | 6 min read

Anti-aging company – Five Alarm Bio – reveal their discoveries on safe and effective treatments for age-associated diseases and disabilities

Discovery & Development Formulation

Llamas – and Yeast Display – to the Rescue

| Jamie Irvine | 2 min read

Modified screening process optimizes nanobodies for sustainable COVID-19 treatments derived from llamas.

Discovery & Development Drug Delivery

Power List Perspectives: Challenges Facing Cell and Gene Therapy

| Jamie Irvine

Leading pharma industry experts discuss the most pertinent challenges facing cell and gene therapy

Discovery & Development Drug Discovery

Meet the New Wave of Therapeutic Antibodies

| Sponsored by Bio-Rad Laboratories | 6 min read

How increased biological understanding and advanced technology are generating new antibody-based modalities with exciting potential.

Discovery & Development Drug Discovery

Retinal Regeneration

| 3 min read

Endogena Therapeutics CEO Matthias Steger discusses fast track FDA approval for EA-2353, a new drug for the treatment of retinitis pigmentosa

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register